[1]
|
Stone, J.H., Khosroshahi, A., Deshpande, V., et al. (2012) Recommendations for the Nomenclature of IgG4-Related Disease and Its Individual Organ System Manifestations. Arthritis & Rheumatism, 64, 3061-3067.
https://doi.org/10.1002/art.34593
|
[2]
|
Kamisawa, T., Zen, Y., Pillai, S. and Stone, J.H. (2015) IgG4-Related Dis-ease. Lancet, 385, 1460-1471.
https://doi.org/10.1016/S0140-6736(14)60720-0
|
[3]
|
张文, 董凌莉, 朱剑, 刘燕鹰, 赵岩, 曾小峰, 张抒. IgG4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3): 192-206.
|
[4]
|
申媛文, 林鹭, 郁胜强. IgG4相关性疾病的管理和治疗: 2015年国际共识解读[J]. 中国实用内科杂志, 2015, 35(12): 1011-1013.
|
[5]
|
季兰岚, 张卓莉. IgG4相关疾病诊断及治疗的国际专家共识[J]. 中华风湿病学杂志, 2016, 20(8): 576.
|
[6]
|
Takahashi, H., Yamamoto, M., Suzuki, C., et al. (2010) The Birthday of a New Syndrome: IgG4-Related Diseases Constitute a Clinical Entity. Autoimmunity Reviews, 9, 591-594. https://doi.org/10.1016/j.autrev.2010.05.003
|
[7]
|
Stone, J.H., Zen, Y. and Deshpande, V. (2012) IgG4-Related Disease. The New England Journal of Medicine, 366, 539-551. https://doi.org/10.1056/NEJMra1104650
|
[8]
|
Ebbo, M., Daniel, L., Pavic, M., et al. (2012) IgG4-Related Systemic Disease: Features and Treatment Response in a French Cohort: Results of a Multicenter Registry. Medicine, 91, 49-56.
https://doi.org/10.1097/MD.0b013e3182433d77
|
[9]
|
Raina, A., Yadav, D., Krasinskas, A.M., et al. (2009) Evalu-ation and Management of Autoimmune Pancreatitis: Experience at a Large US Center. American Journal of Gastroenter-ology, 104, 2295-2306.
https://doi.org/10.1038/ajg.2009.325
|
[10]
|
Lanzillotta, M., Fernàndez-Codina, A., Culver, E., et al. (2021) Emerging Therapy Options for IgG4-Related Disease. Expert Review of Clinical Immunology, 17, 471-483. https://doi.org/10.1080/1744666X.2021.1902310
|
[11]
|
Yoshifuji, H. and Umehara, H. (2022) Glucocorticoids in the Treatment of IgG4-Related Disease-Prospects for New International Treatment Guidelines. Modern Rheumatology, Article ID: roac097. https://doi.org/10.1093/mr/roac097
|
[12]
|
Khosroshahi, A., Wallace, Z.S., Crowe, J.L., et al. (2015) International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthri-tis & Rheumatology, 67, 1688-1699.
https://doi.org/10.1002/art.39132
|
[13]
|
Zhang, W. and Stone, J. (2019) Management of IgG4 Related Disease. Lan-cet Rheumatology, 1, 55-65.
https://doi.org/10.1016/S2665-9913(19)30017-7
|
[14]
|
Wu, Q., Chang, J., Chen, H., et al. (2017) Efficacy between High and Medium Doses of Glucocorticoid Therapy in Remission Induction of IgG4-Related Diseases: A Preliminary Randomized Controlled Trial. International Journal of Rheumatic Diseases, 20, 639-646. https://doi.org/10.1111/1756-185X.13088
|
[15]
|
Li, J., Peng, Y., Zhang, Y., et al. (2020) Identifying Clinical Sub-groups in IgG4-Related Disease Patients Using Cluster Analysis and IgG4-RD Composite score. Arthritis Research & Therapy, 22, Article No. 7.
https://doi.org/10.1186/s13075-019-2090-9
|
[16]
|
Fei, Y., Peng, Y., et al. (2019) Efficacy and Safety of Low Dose Mycophenolate Mofetil Treatment for Immunoglobulin G4-Related Disease: A Randomized Clinical Trial. Rheumatology, 58, 52-60.
https://doi.org/10.1093/rheumatology/key227
|
[17]
|
Wang, L., Zhang, P., Wang, M., et al. (2018) Failure of Remis-sion Induction by Glucocorticoids Alone or in Combination with Immunosuppressive Agents in IgG4-Related Disease: A Prospective Study of 215 Patients. Arthritis Research & Therapy, 20, Article No. 65. https://doi.org/10.1186/s13075-018-1567-2
|
[18]
|
Liu, Y., Zeng, Q., Zhu, L., et al. (2020) Relapse Predictors and Serologically Unstable Condition of IgG4-Related Disease: A Large Chinese Cohort. Rheumatology, 59, 2115-2123. https://doi.org/10.1093/rheumatology/kez669
|
[19]
|
Fukui, S., Nakai, T., Kawaai, S., et al. (2022) Advantages of an Alternate-Day Glucocorticoid Treatment Strategy for the Treatment of IgG4-Related Disease: A Preliminary Retrospec-tive Cohort Study. Medicine, 101, e30932.
https://doi.org/10.1097/MD.0000000000030932
|